Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25234342 | 0.91 | GPR119 (0.49) | GPR119ACACBEPHX2USP2SMN1; SMN2 | |
| SCHEMBL22675692 | 0.88 | EPHX2 (0.41) | GPR119ACACBEPHX2USP2SMN1; SMN2 | |
| SCHEMBL6114742 | 0.85 | CYP11B2 (0.46) | CYP11B2SCD5GPR119ACACBEPHX2 | |
| SCHEMBL24267308 | 0.85 | CYP11B2 (0.46) | CYP11B2SCD5GPR119ACACBEPHX2 | |
| SCHEMBL27373862 | 0.85 | CYP11B2 (0.46) | CYP11B2SCD5GPR119ACACBEPHX2 | |
| SCHEMBL27372736 | 0.85 | CYP11B2 (0.46) | CYP11B2SCD5GPR119ACACBEPHX2 | |
| SCHEMBL16122895 | 0.85 | CYP11B2 (0.42) | CYP11B2SCD5GPR119ACACBEPHX2 | |
| SCHEMBL20461156 | 0.84 | GPR119 (0.47) | GPR119EPHX2USP2SMN1; SMN2 | |
| SCHEMBL16979064 | 0.84 | CYP11B2 (0.46) | CYP11B2SCD5GPR119ACACBEPHX2 | |
| SCHEMBL9994757 | 0.84 | CYP11B2 (0.46) | CYP11B2SCD5GPR119ACACBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | disclosed |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9669013-B2 | Bicyclic aza compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | CYP11B2 532/4885SCD5 3733/4885GPR119 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.